BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 891 | Download: 823
Publication Name World Journal of Clinical Oncology
Manuscript ID 10447
Country/Territory United States
Received
2014-04-01 10:06
Peer-Review Started
2014-04-02 21:34
To Make the First Decision
2014-04-28 14:31
Return for Revision
2014-04-30 18:03
Revised
2014-05-14 04:39
Second Decision
2014-06-11 14:11
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-06-11 14:31
Articles in Press
2014-06-11 15:03
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-07-21 16:07
Publish the Manuscript Online
2014-08-01 15:17
ISSN 2218-4333 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Review
Article Title Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines
Manuscript Source Invited Manuscript
All Author List Jennifer A Crozier, Abhisek Swaika and Alvaro Moreno-Aspitia
Funding Agency and Grant Number
Corresponding Author Alvaro Moreno-Aspitia, MD, Associate Professor of Medicine, Department of Hematology and Oncology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, United States. morenoaspitia.alvaro@mayo.edu
Key Words Breast cancer; Adjuvant; Neoadjuvant; Chemotherapy; Anthracyclines
Core Tip A better understanding of the tumor biology along with other effective novel therapeutic options, have revolutionized the treatment for breast cancer. The role of anthracyclines has come under close scrutiny, especially in the adjuvant setting for patients with early stage breast cancer and those with low or intermediate risk of disease recurrence, as per the recent studies. However, in patients with a high risk of relapse, anthracyclines still hold promise. Ongoing clinical trials are underway to further define the role of anthracyclines in such a patient population.
Publish Date 2014-08-01 15:17
Citation Crozier JA, Swaika A, Moreno-Aspitia A. Adjuvant chemotherapy in breast cancer: To use or not to use, the anthracyclines. World J Clin Oncol 2014; 5(3): 529-538
URL http://www.wjgnet.com/2218-4333/full/v5/i3/529.htm
DOI http://dx.doi.org/10.5306/wjco.v5.i3.529
Full Article (PDF) WJCO-5-529.pdf
Full Article (Word) WJCO-5-529.doc
Manuscript File 10447-Review.docx
Answering Reviewers 10447-Answering reviewers.pdf
Copyright License Agreement 10447-Copyright assignment.pdf
Peer-review Report 10447-Peer review(s).pdf
Scientific Misconduct Check 10447-CrossCheck.jpg
Scientific Editor Work List 10447-Scientific editor work list.pdf